Interventional radiology

Contrast Media Injectors Market Worth $1.8 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, September 18, 2019
Medical physics, Medical imaging, Medicine, Interventional radiology, Radiology, Health, Applied sciences

Based on application, the Contrast Media Injectors Market is segmented into radiology, interventional radiology, and interventional cardiology.

Key Points: 
  • Based on application, the Contrast Media Injectors Market is segmented into radiology, interventional radiology, and interventional cardiology.
  • In 2018, the interventional cardiology segment had the highest growth rate of the Contrast Media Injectors Market.
  • Based on end-user, the Contrast Media Injectors Market is segmented into hospitals and diagnostic imaging centers.
  • The hospital segment commanded the highest growth rate of the global Contrast Media Injectors Market in 2018.

The global neurovascular devices market is expected to reach US$ 3,878.51 Mn in 2027 from US$ 2,919.41 Mn in 2018

Retrieved on: 
Tuesday, September 17, 2019
Medicine, Medical specialties, Interventional radiology, Clinical medicine, Vascular diseases, Angioplasty, Embolization, Aneurysm, Minimally invasive procedure

NEW YORK, Sept. 17, 2019 /PRNewswire/ -- The global neurovascular devices market is expected to reach US$ 3,878.51 Mn in 2027 from US$ 2,919.41 Mn in 2018.

Key Points: 
  • NEW YORK, Sept. 17, 2019 /PRNewswire/ -- The global neurovascular devices market is expected to reach US$ 3,878.51 Mn in 2027 from US$ 2,919.41 Mn in 2018.
  • The neurovascular devices market is estimated to grow with a CAGR of 3.2% from 2019-2027.
  • The market is driven by the factors such as, increasing incidences of neurovascular diseases, rising demand for minimally invasive procedures, and significantly growing aging population.
  • Global neurovascular devices market was segmented by product, application and end user.On the basis of the product the market is segmented as neurothrombectomy devices, aneurysm coiling & embolization devices, cerebral balloon angioplasty & stenting systems and support devices.

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease

Retrieved on: 
Tuesday, September 17, 2019
Medicine, Medical specialties, Interventional radiology, Breakthrough therapy, Immunosuppressants, Lactams, Polyenes, Sirolimus, Angioplasty, Peripheral artery disease, Health care

Virtue SEBs unique design enables delivery of sustained-release sirolimus during angioplasty without the need for coating or permanent implant.

Key Points: 
  • Virtue SEBs unique design enables delivery of sustained-release sirolimus during angioplasty without the need for coating or permanent implant.
  • This highly differentiated design makes this product the ideal candidate for Breakthrough Device Designation in BTK peripheral artery disease, said James P. Zidar, MD, FACC, FSCAI, clinical professor of medicine, UNC Health Systems, physician-in-chief, Heart & Vascular Corporate.
  • Adding a proven anti-restenotic agent like sirolimus has the potential to enhance this treatment approach and drive better patient outcomes.
  • Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective treatment option for life-threatening or irreversibly debilitating diseases.

Results From 20 Highly Anticipated Vascular Interventional Clinical Trials to Be Presented for the First Time at VIVA19

Retrieved on: 
Monday, September 16, 2019
Medicine, Interventional radiology, Vascular surgery, Health care, Health, Interventional cardiology, Vascular Medicine, Radiology, Katharine L. Krol, Anne C. Roberts

VIVA (Vascular InterVentional Advances) is an annual vascular education symposium that brings together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world.

Key Points: 
  • VIVA (Vascular InterVentional Advances) is an annual vascular education symposium that brings together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world.
  • Attendees include an international audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists.
  • The trial results and data will be presented for the first time during the meeting on Tuesday and Wednesday and highlighted in scheduled press conferences on Monday and Tuesday.
  • Our team of specialists in vascular medicine, interventional cardiology, interventional radiology, and vascular surgery is driven by the passion to advance the field and improve patient outcomes.

The European Commission Horizon 2020 Program Backs Filterlex's Embolic Protection Device - CAPTIS

Retrieved on: 
Monday, September 16, 2019
RTT, Catheter, Interventional radiology, Stroke

Filterlex develops the CAPTIS, a full-body embolic protection device to reduce the risk of stroke and other complications during catheter-based structural heart procedures.

Key Points: 
  • Filterlex develops the CAPTIS, a full-body embolic protection device to reduce the risk of stroke and other complications during catheter-based structural heart procedures.
  • The CAPTIS device is a next-generation, full-body embolic protection device, easily and intuitively deployed and retrieved.
  • Our mission is to develop and market the next generation embolic protection device that will provide embolic protection for the arterial bed during left-heart catheter-based procedures.
  • This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 881076.

The European Commission Horizon 2020 Program Backs Filterlex's Embolic Protection Device - CAPTIS

Retrieved on: 
Monday, September 16, 2019
RTT, Catheter, Interventional radiology, Stroke

Filterlex develops the CAPTIS, a full-body embolic protection device to reduce the risk of stroke and other complications during catheter-based structural heart procedures.

Key Points: 
  • Filterlex develops the CAPTIS, a full-body embolic protection device to reduce the risk of stroke and other complications during catheter-based structural heart procedures.
  • The CAPTIS device is a next-generation, full-body embolic protection device, easily and intuitively deployed and retrieved.
  • Our mission is to develop and market the next generation embolic protection device that will provide embolic protection for the arterial bed during left-heart catheter-based procedures.
  • This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 881076.

Intact Vascular to Announce One-Year Data from TOBA III Clinical Trial

Retrieved on: 
Monday, September 16, 2019
Cardiology, Health, Medical devices, Research, Surgery, Hospitals, Science, Clinical trials, Medical specialties, Interventional radiology, Medicine, Angioplasty, Clinical medicine, Peripheral artery disease, Surgical specialties, Medical imaging, Vascular surgery

The TOBA III data being presented at this years TCT meeting augments the already robust clinical evidence supporting the use of Tack implants to treat post-angioplasty dissections, commented Peter Schneider, M.D., Co-Founder and Chief Medical Officer of Intact Vascular.

Key Points: 
  • The TOBA III data being presented at this years TCT meeting augments the already robust clinical evidence supporting the use of Tack implants to treat post-angioplasty dissections, commented Peter Schneider, M.D., Co-Founder and Chief Medical Officer of Intact Vascular.
  • We look forward to sharing the findings of the TOBA III trial and further demonstrating the impact this new, minimal metal therapeutic paradigm offers for patients suffering from peripheral arterial disease.
  • Intact Vascular is a privately held medical device company that develops minimally- invasive peripheral vascular products.
  • Intact Vascular is sponsoring three clinical trials to evaluate its Tack Endovascular System: TOBA II, TOBA II BTK and TOBA III.

Centerline Biomedical Wins SBIR Phase II Award from NIH

Retrieved on: 
Thursday, September 12, 2019
Health, Interventional radiology, Medical devices, Cleveland Clinic, Stent, National Institutes of Health, Articles

CLEVELAND, Sept. 12, 2019 /PRNewswire/ --Centerline Biomedical, Inc., announced that it has been awarded its third small business grant from the NIH National Heart, Lung, and Blood Institute, with Cleveland Clinic as a subawardee.

Key Points: 
  • CLEVELAND, Sept. 12, 2019 /PRNewswire/ --Centerline Biomedical, Inc., announced that it has been awarded its third small business grant from the NIH National Heart, Lung, and Blood Institute, with Cleveland Clinic as a subawardee.
  • This Phase II grant, with a total budget of approximately $1.5 million, will support advancement of the company's Intra-Operative Positioning System (IOPS) with augmented reality 3D guidance, navigation, and control (3D-GNC) for placing endovascular stents.
  • By simplifying complex procedures and making them faster, safer, and more accurate, Centerline hopes to decrease costs while improving access to care.
  • This Phase II work will culminate in a first-in-human study and pave the way to realizing the full clinical and economic benefits the technology has to offer.

Rex Medical Receives 510k Clearance for Revolution™ Peripheral Atherectomy System

Retrieved on: 
Thursday, September 12, 2019
Oncology, Medical devices, Other Manufacturing, Clinical trials, Surgery, Cardiology, FDA, Health, Manufacturing, Medical specialties, Circulatory system, Medicine, Vascular surgery, Interventional radiology, Atherectomy, RTT, Vascular diseases, Thrombus, Atherosclerosis, Peripheral vascular system, Revascularization

Rex Medical, L.P. , a medical device design and development company, today announced that it has received 510k Clearance from the U.S. Food and Drug Administration (FDA) for the Revolution Peripheral Atherectomy System.

Key Points: 
  • Rex Medical, L.P. , a medical device design and development company, today announced that it has received 510k Clearance from the U.S. Food and Drug Administration (FDA) for the Revolution Peripheral Atherectomy System.
  • The results of this pivotal trial demonstrated the safety and effectiveness of the Revolution Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization in 121 subjects with femoropopliteal/tibial occlusive disease.
  • The Revolution device is indicated for atherectomy of the peripheral vasculature and to break apart and remove thrombus from the peripheral arteries in patients with occlusive atherosclerotic disease.
  • The Rex Medical Revolution Peripheral Atherectomy System is an innovative and ergonomically designed low profile rotational atherectomy system (140,000 RPM) with continuous mechanical aspiration for below-the-knee (BTK) and above-the-knee (ATK) applications including multiple plaque morphologies ranging from thrombus and soft plaque to severely calcified lesions and chronic total occlusions (CTOs).

Endospan Enters Into Strategic Distribution Agreement With CryoLife

Retrieved on: 
Thursday, September 12, 2019
Other Health, Radiology, Pharmaceutical, Optical, Oncology, Mental health, Surgery, Medical devices, Infectious diseases, Hospitals, Genetics, Fitness & Nutrition, Dental, Veterinary, Clinical trials, Nursing, Cardiology, Medical Supplies, Biotechnology, FDA, Alternative medicine, Diabetes, AIDS, Health, Stem cells, Practice Management, Physical therapy, Managed care, General Health, Medical specialties, Medicine, Angiology, Vascular diseases, Interventional radiology, Vascular surgery, Aneurysm, Stent, Endovascular aneurysm repair, Thoracic aortic aneurysm

Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, today announced it has entered into strategic distribution and credit facility agreements with CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease.

Key Points: 
  • Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, today announced it has entered into strategic distribution and credit facility agreements with CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease.
  • Under the terms of the agreement, CryoLife will have exclusive European distribution rights to NEXUS, the first off-the-shelf endovascular stent graft system approved for the repair of both aneurysms and dissections in the aortic arch.
  • Additionally, CryoLife will provide up to $15 million in debt financing to Endospan subject to progress on the U.S. clinical development program for the NEXUS Stent Graft System.
  • We are very pleased to announce a European distribution agreement with CryoLife that allows us to leverage their companys depth of experience and proven capabilities in the endo-vascular market together with our combined relationships with European opinion leaders, said Kevin Mayberry, CEO of Endospan.